Johnni Cansler, APRN
Psychiatric/Mental Health · Portland, ORNPI 1144709403
Payments from drug & device makers
Across 1,066 payments — averaging $496.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$468K
- Axsome Therapeutics, Inc.$52K
- Vanda Pharmaceuticals Inc.$6K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$632
- Alkermes, Inc.$485
- Otsuka America Pharmaceutical, Inc.$428
- plus $1K from 10 others
What the payments were for
- Consulting fees$31,6506%
- Speaking & faculty fees$400,75576%
- Travel & lodging$77,12315%
- Food & beverage$19,4204%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 796 | $467,612 |
| Axsome Therapeutics, Inc. | 109 | $52,187 |
| Vanda Pharmaceuticals Inc. | 13 | $6,285 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $632 |
| Alkermes, Inc. | 20 | $485 |
| Otsuka America Pharmaceutical, Inc. | 21 | $428 |
| Corium, LLC | 10 | $288 |
| Lundbeck LLC | 16 | $281 |
| Johnson & Johnson | 17 | $276 |
| Neurocrine Biosciences, Inc. | 4 | $203 |
| Sunovion Pharmaceuticals Inc. | 21 | $198 |
| Merck | 4 | $67 |
| Ironshore Pharmaceuticals Inc. | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$529,042 in reported general payments places this provider in the 95th percentile of 540 psychiatric/mental health providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $143,918 |
| VraylarCariprazine Hcl | 91 | $128,685 |
| AuvelityDextromethorphan Hbr/Bupropion | 74 | $82,427 |
| CaplytaLumateperone Tosylate | 33 | $53,364 |
| RexultiBrexpiprazole | 28 | $40,223 |
| QelbreeViloxazine Hcl | 15 | $15,461 |
| BelsomraSuvorexant | 12 | $5,066 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 23 | $4,958 |
| Aripiprazole | 54 | $2,010 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 79 | $1,682 |
| Gabapentin | 99 | $1,496 |
| Vilazodone Hcl | 13 | $1,135 |
| Prazosin Hcl | 41 | $1,031 |
| Hydroxyzine Pamoate | 47 | $964 |
| Hydroxyzine Hcl | 21 | $807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $203 | $143,91817 claims |
| AbbVieVraylar | $467,612 | $128,68591 claims |
| Axsome Therapeutics, Inc.Auvelity | $52,187 | $82,42774 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $632 | $53,36433 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $428 | $40,22328 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $21 | $15,46115 claims |
| MerckBelsomra | $67 | $5,06612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 540 psychiatric/mental health providers in Oregon.
Other psychiatric/mental health in Portland
- Tina Matthews-HayesPortland$787K
- Jill CarterPortland$416K
- Michelle VoegelsPortland$29K
- Corinne RekartPortland$4K
- Kalesha JonesPortland$2K
- Tamara JohnsonPortland$2K
- Orawan LaochumnanvanitPortland$2K
- Samantha LauPortland$2K
- Rebecca BermanPortland$2K
- Tara CandelaPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.